Dr Foote on the Use of Tucatinib Plus Trastuzumab in HER2-Amplified mCRC
Micheal Foote, MD, discusses the use of tucatinib plus trastuzumab compared with chemotherapy in the management of HER2-amplified metastatic colorectal cancer.
Read More
Dr. Foote on the Quest to Determine Optimal Sequencing in Late-line mCRC
Micheal Foote, MD, discusses the quest to determine optimal sequencing of current therapeutics in the third-line setting and beyond for metastatic colorectal cancer.
Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL
Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment
Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer
Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC